Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J. Motzer, Theodore Stewart Gourdin, Camillo Porta et al.|Journal of Clinical Oncology|2024Cited by 170
7131 POSTER Optimizing the Sequencial Treatment of Metastatic Renal Cell Carcinoma (MRCC) – a Retrospective, Multicenter, Analysis of 40 Patients Treated With Either Sorafenib, an mTOR Inhibitor (mTORI) and Sunitinib, or Sunitinib, an mTORI and SorafenibCamillo Porta, Ilaria Imarisio, Chiara Paglino et al.|European Journal of Cancer|2011Cited by 7
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.R Motzer, Manuela Schmidinger, Begoña P. Valderrama et al.|Journal of Clinical Oncology|2026Cited by 4
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.Chiara Paglino, Camillo Porta, Giuseppe Procopio et al.|PubMed|2013Cited by 3
Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).Toni K. Choueiri, Robert J. Motzer, Thomas Powles et al.|Journal of Clinical Oncology|2016Cited by 2